Tag: Prostate Cancer

PCa17: What to expect in future prostate cancer management

The number of promising biomarkers at different molecular levels are increasing, accompanied by numerous testing in the market, but cancer experts say independent and prospective validation is crucial to help the medical community eventually provide optimal care to cancer...

PCa17: Interactive, compact meeting opens in Vienna

Challenges in diagnosis, staging and patient selection were among the issues taken up in the first plenary session of the EAU Update on Prostate Cancer (PCa17) opened in Vienna today. With more than 300 participants including faculty and exhibitors,...

Young Urologists Competition presents fresh insights at BALTIC17

Fresh perspectives on various urological conditions were presented during the highly-anticipated Young Urologists Competition session of the 4th Baltic Meeting in conjunction with the EAU (BALTIC17) held for the second time in Vilnius, Lithuania. Chaired by Professors Bob Djavan (AT) and Michel...

BALTIC17 looks into best practices in uro-oncology

Vilnius welcomed more than 250 participants to the 4th Baltic Meeting (BALTIC17) with the opening session focusing on best and current practices in diagnosing and managing urological cancers particularly the role of biopsy techniques, imaging tools, quality of life...
Highlights from the EAU17 Souvenir Session with Chris Chapple

EAU17: Highlights from the Souvenir Session

Highlights of the five-day 32nd Annual EAU Congress were reported today in the concluding session with members of the EAU Scientific Committee presenting the most noteworthy developments and conclusions in prostate disease, urological cancers, systemic therapy in GU cancer,...
ProtecT trial shows classical risk categories don’t help

EAU17: ProtecT trial shows classical risk categories don’t help

The classical risk categories used to stage prostate cancer disease do not aid clinical decision-making as much as PSA, biopsy, Gleason score, biopsy results and other measurements, according to an expert who commented during the Late-Breaking news segment of...

EAU17: Thematic Session explores personalised medicine in prostate cancer

Knowledge of overexpressed oncogenes and the importance of the transcription factor ETS-related gene (ERG) and cytokines in relation to individualised therapy in prostate cancer, were examined today during the “Personalised medicine in urological oncology” session chaired by Prof. Zoran Culig...